Intra-Cellular Therapies, Inc.
Organic compounds
Last updated:
Abstract:
This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT.sub.2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D.sub.1/D.sub.2 receptor signaling systems, and/or the treatment of residual symptoms.
Status:
Grant
Type:
Utility
Filling date:
10 Feb 2020
Issue date:
26 Jan 2021